がんワクチン市場：技術、治療法、用途別-2025～2030年の世界予測

がんワクチン市場は、2023年に179億米ドルと評価され、2024年には205億6,000万米ドルに達すると予測され、CAGR 15.37％で成長し、2030年には487億1,000万米ドルに達すると予測されています。

がんワクチンは、予防的および治療的応用の両方を目的とした、腫瘍学における極めて重要な進歩を表しています。これらのワクチンは、体内の免疫系を刺激してがん細胞を識別・破壊し、リスクの高い人の発症を予防したり、既存の悪性腫瘍を治療したりします。がんワクチンの対象範囲は広く、子宮頸がん、肝臓がん、胃がんなど様々ながんを対象としており、免疫療法に対する意識の高まりと技術革新がその原動力となっています。その必要性は、がん罹患率の増加により、より的を絞った効果的な治療法に対する需要が高まっていることに起因します。主な用途には、HPVワクチンのような予防ワクチンや、メラノーマのようながんの再発や転移を抑える治療タイプがあります。最終用途の範囲は病院、がん研究機関、がん専門クリニックに及び、米国、欧州、アジア太平洋地域が重要な市場となっています。

抗原探索の進歩、バイオテクノロジー研究開発への投資増加、官民連携による資金調達強化など、重要な成長要因が明らかになった。個別化医療への注目の高まりや、精密治療愛好家にとって魅力的なネオアンチゲンをベースとしたワクチン開発には機が熟しています。起業家たちは、画期的なワクチン試験のためのパートナーシップを模索し、抗原同定の改良のためにAIを活用して、こうした動向を活用すべきです。しかし、厳しい規制状況、高い開発コスト、限られた熟練人材といった課題が大きなハードルとなっています。さらに、臨床試験プロセスに時間がかかることや、がんの種類によって有効性が異なることも、市場の成長を制約しています。

最も革新的な分野としては、がんワクチンとチェックポイント阻害剤やその他の免疫調節剤を統合した併用療法の探求が挙げられます。費用対効果の高いワクチン製造プロセスの開発に重点を置くことで、財政的な制約を緩和することができます。ゲノム解読の進歩を活用することで、ワクチン反応をさらに個別化し、患者の転帰を改善することができます。要するに、がんワクチン市場はダイナミックであり、障壁を効果的に乗り越えさえすれば、イノベーションと戦略的提携によって大きく成長する可能性を秘めています。

市場力学：急速に進化するがんワクチン市場の主要市場インサイトを公開

がんワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 老年人口の増加に伴うがん患者の増加
  • がん治療に対する患者の意識の高まり
  • ヒト乳頭腫ウイルス（HPV）感染率の増加
• 市場抑制要因
  • 開発コストの高さ
• 市場機会
  • がんワクチン開発への投資と政府資金の増加
  • がんワクチンの技術開発
• 市場の課題
  • ワクチン1本の製造に要する時間の長さ

ポーターの5つの力：がんワクチン市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：がんワクチン市場における外部からの影響の把握

外部マクロ環境要因は、がんワクチン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析がんワクチン市場における競合情勢の把握

がんワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスがんワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、がんワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨がんワクチン市場における成功への道筋を描く

がんワクチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢化人口の増加に伴うがん患者数の増加
    • がん治療に対する患者の意識の高まり
    • ヒトパピローマウイルス（HPV）感染率の増加
  • 抑制要因
    • がんワクチンの開発コストが高い
  • 機会
    • がんワクチンの開発への投資と政府資金の増加
    • がんワクチンにおける技術開発
  • 課題
    • 1つのワクチンの製造には長い期間が必要
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 がんワクチン市場：技術別

• 抗原
• 樹状細胞
• 組み換えがんワクチン
• ウイルスベクターとDNAがんワクチン
• 全細胞がんワクチン

第7章 がんワクチン市場治療方法別

• 予防ワクチン
• 治療ワクチン

第8章 がんワクチン市場：用途別

• 子宮頸がん
• 前立腺がん

第9章 南北アメリカのがんワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のがんワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのがんワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Advaxis Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bayer AG
• Celldex Therapeutics
• Dynavax Technologies
• GSK PLC
• Helsinn Healthcare SA
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis International AG
• Pfizer Inc.
• Sanofi SA
• Sanpower Group Co., Ltd.
• Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. CANCER VACCINES MARKET RESEARCH PROCESS
• FIGURE 2. CANCER VACCINES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CANCER VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CANCER VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CANCER VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CANCER VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CANCER VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CANCER VACCINES MARKET DYNAMICS
• TABLE 7. GLOBAL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY ANTIGEN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY RECOMBINANT CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY VIRAL VECTOR & DNA CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CANCER VACCINES MARKET SIZE, BY WHOLE-CELL CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CANCER VACCINES MARKET SIZE, BY PREVENTIVE VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CANCER VACCINES MARKET SIZE, BY THERAPEUTIC VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CANCER VACCINES MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CANCER VACCINES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. CANADA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 30. CANADA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 31. CANADA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES CANCER VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. CHINA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 47. CHINA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 48. CHINA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. INDIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 50. INDIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 51. INDIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. ITALY CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 102. ITALY CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 103. ITALY CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. POLAND CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 114. POLAND CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 115. POLAND CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. QATAR CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 117. QATAR CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 118. QATAR CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. CANCER VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. CANCER VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

The Cancer Vaccines Market was valued at USD 17.90 billion in 2023, expected to reach USD 20.56 billion in 2024, and is projected to grow at a CAGR of 15.37%, to USD 48.71 billion by 2030.

Cancer vaccines represent a pivotal advancement in oncology, aimed at both prophylactic and therapeutic applications. These vaccines function by stimulating the body's immune system to identify and destroy cancer cells, either preventing onset in high-risk individuals or treating existing malignancies. The scope of cancer vaccines is broad, addressing various cancers such as cervical, liver, and gastric cancers, driven by heightened awareness and technological innovation in immunotherapy. Necessity arises from the growing cancer prevalence, driving demand for more targeted, effective treatment modalities. Key applications include preventive vaccines like the HPV vaccine and therapeutic types aiding in reducing recurrence and metastasis in cancers such as melanoma. The end-use scope spans hospitals, cancer research institutes, and specialized oncology clinics, with the U.S., Europe, and Asia-Pacific regions being critical markets.

Insights reveal significant growth factors, including advancements in antigen discovery, rising investment in biotech R&D, and collaborations between public-private sectors enhancing funding. Opportunities are ripe in the growing focus on personalized medicine and the development of neoantigen-based vaccines, appealing to precision therapy enthusiasts. Entrepreneurs should explore partnerships for breakthrough vaccine trials and leverage AI for improved antigen identification to capitalize on these trends. However, challenges such as stringent regulatory landscapes, high development costs, and limited skilled personnel pose significant hurdles. Additionally, market growth is constrained by slow clinical trial processes and varying efficacy across cancer types.

The best innovation areas include exploring combination therapies integrating cancer vaccines with checkpoint inhibitors and other immunomodulatory agents. Emphasis on developing cost-effective vaccine manufacturing processes can mitigate financial restraints. Leveraging advancements in genome sequencing can further personalize vaccine responses, leading to better patient outcomes. In essence, the cancer vaccines market is dynamic, with vast potential for growth driven by innovation and strategic alliances, provided the barriers are effectively navigated.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Vaccines Market

The Cancer Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increase in number of cancer patients along with growing geriatric population
  • Surge in patient awareness towards cancer therapy
  • Increase in prevalence of human papilloma virus (HPV) infections
• Market Restraints
  • High cost for developing cancer vaccines
• Market Opportunities
  • Increase in investments and government funding in development of cancer vaccines
  • Technological developments in cancer vaccines
• Market Challenges
  • Longer time span required for manufacturing a single vaccine

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Vaccines Market

A detailed market share analysis in the Cancer Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Vaccines Market

A strategic analysis of the Cancer Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Vaccines Market, highlighting leading vendors and their innovative profiles. These include Advaxis Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Celldex Therapeutics, Dynavax Technologies, GSK PLC, Helsinn Healthcare SA, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi SA, Sanpower Group Co., Ltd., and Sun Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Antigen, Dendritic Cells, Recombinant Cancer Vaccines, Viral Vector & DNA Cancer Vaccines, and Whole-cell Cancer Vaccines.
• Based on Treatment Method, market is studied across Preventive Vaccine and Therapeutic Vaccine.
• Based on Application, market is studied across Cervical Cancer and Prostate Cancer.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in number of cancer patients along with growing geriatric population
    • 5.1.1.2. Surge in patient awareness towards cancer therapy
    • 5.1.1.3. Increase in prevalence of human papilloma virus (HPV) infections
  • 5.1.2. Restraints
    • 5.1.2.1. High cost for developing cancer vaccines
  • 5.1.3. Opportunities
    • 5.1.3.1. Increase in investments and government funding in development of cancer vaccines
    • 5.1.3.2. Technological developments in cancer vaccines
  • 5.1.4. Challenges
    • 5.1.4.1. Longer time span required for manufacturing a single vaccine
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer Vaccines Market, by Technology

• 6.1. Introduction
• 6.2. Antigen
• 6.3. Dendritic Cells
• 6.4. Recombinant Cancer Vaccines
• 6.5. Viral Vector & DNA Cancer Vaccines
• 6.6. Whole-cell Cancer Vaccines

7. Cancer Vaccines Market, by Treatment Method

• 7.1. Introduction
• 7.2. Preventive Vaccine
• 7.3. Therapeutic Vaccine

8. Cancer Vaccines Market, by Application

• 8.1. Introduction
• 8.2. Cervical Cancer
• 8.3. Prostate Cancer

9. Americas Cancer Vaccines Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cancer Vaccines Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Vaccines Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Advaxis Inc.
• 2. Amgen Inc.
• 3. AstraZeneca PLC
• 4. Bayer AG
• 5. Celldex Therapeutics
• 6. Dynavax Technologies
• 7. GSK PLC
• 8. Helsinn Healthcare SA
• 9. Johnson & Johnson
• 10. Merck & Co., Inc.
• 11. Novartis International AG
• 12. Pfizer Inc.
• 13. Sanofi SA
• 14. Sanpower Group Co., Ltd.
• 15. Sun Pharmaceutical Industries Ltd.